Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamterene
Drug ID BADD_D02275
Description Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side.[A177985] Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy.[T28] Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug.[L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.[L6163] Currently, triamterene is used in the treatment of edema associated with various conditions as monotherapy and is approved for use with other diuretics to enhance diuretic and potassium-sparing effects.[L6166] It is also found in a combination product with hydrochlorothiazide that is used for the management of hypertension or treatment of edema in patients who develop hypokalemia on hydrochlorothiazide alone.
Indications and Usage Triamterene is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.[L6166] Triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy, and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be risked.[L6169] Triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazides.[T28]
Marketing Status approved
ATC Code C03DB02
DrugBank ID DB00384
KEGG ID D00386
MeSH ID D014223
PubChem ID 5546
TTD Drug ID D00NKB
NDC Product Code 52932-0703; 59212-003; 66993-832; 66993-831; 59212-002; 57451-1197; 46438-0034
UNII WS821Z52LQ
Synonyms Triamterene | Urocaudal | Dyrenium | Dytac
Chemical Information
Molecular Formula C12H11N7
CAS Registry Number 396-01-0
SMILES C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Asthenia08.01.01.001--Not Available
Azotaemia20.01.01.001--Not Available
Blood creatinine13.13.01.020--Not Available
Blood urea increased13.13.01.006--Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Fatigue08.01.01.002--
Headache17.14.01.001--
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypokalaemia14.05.03.002--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Photosensitivity reaction23.03.09.003--
Rash23.03.13.001--Not Available
Thrombocytopenia01.08.01.002--Not Available
Vomiting07.01.07.003--
Tubulointerstitial nephritis20.05.02.002--Not Available
Hepatic enzyme abnormal13.03.04.026--Not Available
Chronic kidney disease20.01.03.017--
Acute kidney injury20.01.03.016--
The 1th Page    1    Total 1 Pages